The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
CD4 T Cells and Their Role in Antitumor Immune Responses
Open accessAbstract
The specificity and power of the cellular arm of the immune system may provide new therapeutic approaches to cancer. With the assumption that T cells might be able to recognize and eliminate cancer cells with the same efficiency as virus-infected cells, investigators have searched many years for ways to trigger or amplify the patient's inadequate immune response to tumors. Much attention has been given to the role of CD8+ CTLs because most tumors are MHC class I positive, but negative for MHC class II. Moreover, CD8+ CTLs are able to lyse tumor cells directly upon recognition of peptide–MHC class I complexes expressed by the tumor, and their ability to eradicate large tumor masses in vivo has been demonstrated. The focus in cancer immunology on CD8+ T cell responses is also exemplified by an increasing list of tumor antigens identified by tumor-reactive CD8+ CTLs. CD4+ Th cells have received far less attention, which is remarkable given the pivotal role of these cells in regulating most antigen-specific immune responses. Until now, only a few Th epitopes derived from human tumor antigens recognized by CD4+ Th cells have been identified (1, 2). Three studies published in this issue describe the identification of melanoma antigens that are recognized by CD4+ T cells in the context of MHC class II molecules (3–5). Charting the Th response against human melanoma as well as other tumors is important for the development of optimal anticancer vaccines and for the design of other T cell–related therapeutic modalities in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Self-citationA conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Di Rosa, F., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,342
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,092
Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., & Alber, G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.747 · Cited by 1,983
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Bevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956
Koch, F., Stanzl, U., Jennewein, P., Janke, K., Heufler, C., Kämpgen, E., Romani, N., & Schuler, G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.741 · Cited by 927
Bennett, S. R. M., Carbone, F. R., Karamalis, F., Miller, J. F. A. P., & Heath, W. R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.65 · Cited by 725
Kurts, C., Kosaka, H., Carbone, F. R., Miller, J. F. A. P., & Heath, W. R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.2.239 · Cited by 706
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
Staveley-O’Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., & Levitsky, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1178 · Cited by 704
Ossendorp, F., Mengedé, E., Camps, M., Filius, R., & Melief, C. J. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.693 · Cited by 610
Self-citationGreenberg, P. D. (1991) · Advances in Immunology · doi:10.1016/s0065-2776(08)60778-6 · Cited by 603
Helper activity is required for the in vivo generation of cytotoxic T lymphocytes
Keene, J.-A., & Forman, J. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.3.768 · Cited by 500
Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes
Kiener, P. A., Moran-Davis, P., Rankin, B. M., Wahl, A. F., Aruffo, A., & Hollenbaugh, D. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.10.4917 · Cited by 355
Allan, W., Tabi, Z., Cleary, A., & Doherty, P. C. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.10.3980 · Cited by 331
Greenberg, P. D., Cheever, M. A., & Fefer, A. (1981) · The Journal of experimental medicine · doi:10.1084/jem.154.3.952 · Cited by 312
Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., van der Eb, A. J., & Melief, C. J. M. (1989) · Cell · doi:10.1016/0092-8674(89)90006-8 · Cited by 301
Self-citationAdler, A. J., Marsh, D. W., Yochum, G. S., Guzzo, J. L., Nigam, A., Nelson, W. G., & Pardoll, D. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1555 · Cited by 294
Greenberg, P. D., Kern, D. E., & Cheever, M. A. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1122 · Cited by 292
Tumor Eradication by Adoptive Transfer of Cytototic T Lymphocytes
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60294-8 · Cited by 275
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.
Topalian, S. L., Gonzales, M. I., Parkhurst, M., Li, Y. F., Southwood, S., Sette, A., Rosenberg, S. A., & Robbins, P. F. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.5.1965 · Cited by 257
Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes
Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A. M. M., Boon, T., & van der Bruggen, P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.767 · Cited by 234
Dendritic cells require maturation via CD40 to generate protective antitumor immunity.
Mackey, M. F., Gunn, J. R., Maliszewski, C. R., Kikutani, H., Noelle, R. J., & Barth, R. J. (1998) · PubMed · Cited by 201
Cutting Edge: Dendritic Cells Require Maturation via CD40 to Generate Protective Antitumor Immunity
Mackey, M. F., Gunn, J. R., Maliszewski, C., Kikutani, H., Noelle, R. J., & Barth, R. J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2094 · Cited by 161
Kast, W. M., Bronkhorst, A. M., de Waal, L. P., & Melief, C. J. M. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.164.3.723 · Cited by 140
Self-citationMackey, M., Gunn, J. R., Ting, P. P., Kikutani, H., Dranoff, G., Noelle, R. J., & Barth, R. J. (1997) · PubMed · Cited by 107
Shinde, S. S., Wu, Y. P., Guo, Y., Niu, Q., Xu, J., Grewal, I. S., Flavell, R. A., & Liu, Y. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.7.2764 · Cited by 97
Peripheral tolerance of CD4 T cells following local activation in adolescent mice
Förster, I., & Lieberam, I. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261253 · Cited by 87
Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.
Toes, R. E. M., Blom, R. J. J., van der Voort, E., Offringa, R., Melief, C. J. M., & Kast, W. M. (1996) · PubMed · Cited by 86
Self-citationHalder, T. M., Pawelec, G., Kirkin, A. F., Zeuthen, J., Meyer, H. E., Kun, L., & Kalbacher, H. (1997) · PubMed · Cited by 84
Cassell, D. J., & Forman, J. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb36325.x · Cited by 64
Seung, S. K., Urban, J. L., & Schreiber, H. W. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.3.933 · Cited by 60
CD4+ helper T cells are required for resistance to a highly metastatic murine tumor
Schild, H., Kyewski, B., von Hoegen, P., et al. (1987) · European Journal of Immunology · doi:10.1002/eji.1830171231 · Cited by 51
Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers.
Romerdahl, C. A., & Kripke, M. L. (1988) · PubMed · Cited by 31
Bear, H. D., Süßkind, B., Close, K. A., & Barrett, S. K. (1988) · PubMed · Cited by 26
Cited by
Dendritic cell immunotherapy: mapping the way
Figdor, C. G., de Vries, I. J. M., Lesterhuis, W. J., & Melief, C. J. M. (2004) · Nature Medicine · doi:10.1038/nm1039 · Cited by 945
Self-citationPrognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers
Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N. E. H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1886 · Cited by 598
Bell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A., & Banchereau, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1417 · Cited by 544
“DCs present Ag to CD4 1 T cells (5), which in turn regulate the immune effectors, including Ag-specific effectors such as CD8 1 T cells and B cells as well as nonspecific effectors such as macrophages, eosinophils, and NK cells.”
BackgroundFinke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Xie, Y., Akpinarli, A., Maris, C., Hipkiss, E. L., Lane, M., Kwon, E.-K. M., Muranski, P., Restifo, N. P., & Antony, P. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091921 · Cited by 457
Metadata
- Authors
- Toes, R. E. M., Ossendorp, F., Offringa, R., & Melief, C. J. M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1999-03-01
- Volume
- 189
- Issue
- 5
- Pages
- 753-756
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2040594411
- Cited by
- 508
- References
- 36
- FWCI
- 14.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.